Recent progress in chemotherapy has dramatically increased the survival rates of many pediatric cancers; however, advanced stage NB with metastasis, especially those with genomic amplification of the MYCN oncogene, are frequently resistant to any therapy and the outcome for patients is still very poor (1–3). The gene discussed is MYCN; the disease is neuroblastoma.